Halozyme Therapeutics Increases FY24 Adj. EPS From $3.55-$3.90 To $3.65-$4.05 Vs $3.730 Est; Revenue From $915M-$968M To $935M-$1.015B Vs $947.327M Est.
Portfolio Pulse from Benzinga Newsdesk
Halozyme Therapeutics has increased its FY24 adjusted EPS guidance from $3.55-$3.90 to $3.65-$4.05, compared to the $3.730 estimate. The company also raised its revenue guidance from $915M-$968M to $935M-$1.015B, compared to the $947.327M estimate.
June 06, 2024 | 12:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics has increased its FY24 adjusted EPS and revenue guidance, indicating a positive outlook for the company.
The increase in both EPS and revenue guidance suggests that Halozyme Therapeutics is performing better than expected, which is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100